Disease Burden and Inpatient Management of Children with Acute Respiratory Viral Infections during the Pre-COVID Era in Germany: A Cost-of-Illness Study
Viruses · 2024
DOI: 10.3390/v16040507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Maren Alchikh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Safety Initiative, 10437 Berlin, Germany. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Cost of Illness, Hospitalization. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Respiratory viral infections (RVIs) are common reasons for healthcare consultations. The inpatient management of RVIs consumes significant resources. From 2009 to 2014, we assessed the costs of RVI management in 4776 hospitalized children aged 0–18 years participating in a quality improvement program, where all ILI patients underwent virologic testing at the National Reference Centre followed by detailed recording of their clinical course. The direct (medical or non-medical) and indirect costs of inpatient management outside the ICU (‘non-ICU’) versus management requiring ICU care (‘ICU’) added up to EUR 2767.14 (non-ICU) vs. EUR 29,941.71 (ICU) for influenza, EUR 2713.14 (non-ICU) vs. EUR 16,951.06 (ICU) for RSV infections, and EUR 2767.33 (non-ICU) vs. EUR 14,394.02 (ICU) for human rhinovirus (hRV) infections, respectively. Non-ICU inpatient costs were similar for all eight RVIs studied: influenza, RSV, hRV, adenovirus (hAdV), metapneumovirus (hMPV), parainfluenza virus (hPIV), bocavirus (hBoV), and seasonal coronavirus (hCoV) infections. ICU costs for influenza, however, exceeded all other RVIs. At the time of the study, influenza was the only RVI with antiviral treatment options available for children, but only 9.8% of influenza patients (non-ICU) and 1.5% of ICU patients with influenza received antivirals; only 2.9% were vaccinated. Future studies should investigate the economic impact of treatment and prevention of influenza, COVID-19, and RSV post vaccine introduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vaccine Safety Initiative, 10437 Berlin, Germany.
- Laboratoire Chrono-Environnement, Université Bourgogne Franche-Comté, 25030 Besançon, France.
- ESGREV (ESCMID Respiratory Virus Study Group), 4001 Basel, Switzerland.
- Zuse Institute Berlin, 14195 Berlin, Germany.
- Department of Pulmonology, Capital Institute of Pediatrics, Beijing 100005, China.
- Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Reference Centre for Influenza, Robert Koch-Institute, 13353 Berlin, Germany.
ORCID-Profile: Maren Alchikh, Tim O F Conrad, Patrick E Obermeier, Xiaolin Ma, Onya Opota
Zitieren
APA
Alchikh, M., Conrad, T. O. F., Obermeier, P. E., Ma, X., Schweiger, B., Opota, O., & Rath, B. A. (2024). Disease Burden and Inpatient Management of Children with Acute Respiratory Viral Infections during the Pre-COVID Era in Germany: A Cost-of-Illness Study. Viruses. https://doi.org/10.3390/v16040507
Vancouver
Alchikh M, Conrad TOF, Obermeier PE, Ma X, Schweiger B, Opota O, et al. Disease Burden and Inpatient Management of Children with Acute Respiratory Viral Infections during the Pre-COVID Era in Germany: A Cost-of-Illness Study. Viruses. 2024. doi:10.3390/v16040507
BibTeX
@article{Alchikh2024,
author = {Alchikh, Maren and Conrad, Tim O F and Obermeier, Patrick E and Ma, Xiaolin and Schweiger, Brunhilde and Opota, Onya and Rath, Barbara A},
title = {Disease Burden and Inpatient Management of Children with Acute Respiratory Viral Infections during the Pre-COVID Era in Germany: A Cost-of-Illness Study},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16040507}
}
EUVIMED